Johnson & Johnson (NYSE:JNJ) Shares Sold by Berger Financial Group Inc

Berger Financial Group Inc reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,218 shares of the company’s stock after selling 561 shares during the period. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $5,816,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JNJ. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $32,000. Finally, Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $33,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Bank of America cut their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $171.82.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $154.54 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $371.83 billion, a PE ratio of 23.24, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The business’s fifty day moving average price is $159.48 and its 200 day moving average price is $154.84.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.